• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Qlucore

0.30 SEK+13.16 %10.7, 17.29
Less than 1K followers

QCORE

First North Stockholm

IT Services

Technology

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+13.16 %
-25.31 %
-26.41 %
-38.82 %
-39.56 %
-10.21 %
-93.49 %
-
-98.92 %

Qlucore develops AI-based software for use in the healthcare sector. The company's precision medicine solutions transform genetic data into decision-making data to create the right treatment for patients. The company's first diagnostic test – for blood cancer in children – has been approved and CE-marked. The company also has tests for lung cancer under development, and is developing the Qlucore Omics Explorer analysis software.

Read more
Market cap
12.91M SEK
Turnover
29.77K SEK
Revenue
6.74M
EBIT %
-539.84 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
9.9
2026

Interim report Q1'27

9.9
2026

General meeting '26

26.11
2026

Interim report Q2'27

Press release23.06.2026, 19.20

Qlucore Receives EUR 0.5 Million EU Payment

Qlucore
Press release17.06.2026, 20.30

Qlucore Receives Approval for EUR 0.5 Million EU Payment

Qlucore
Regulatory press release28.05.2026, 08.30

Year-end-report 1 May 2025 - 30 April 2026

Qlucore

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release20.04.2026, 14.00

Qlucore Launches AI-based test for Bladder Cancer

Qlucore
Press release13.04.2026, 10.30

Qlucore Launches AI-based test for Acute Myeloid Leukemia

Qlucore
Regulatory press release26.02.2026, 08.30

Interim report 1 May 2025 - 31 January 2026

Qlucore
Press release23.02.2026, 17.10

Invitation to presentation including Q&A session of Qlucore’s interim report for the period 1 May 2025 – 31 January 2026

Qlucore
Press release18.12.2025, 14.00

New version of Qlucore Omics Explorer with enhanced support for in-depth proteomics analysis

Qlucore
Regulatory press release27.11.2025, 08.30

Interim report 1 May - 31 October 2025

Qlucore
Regulatory press release27.11.2025, 08.20

Disposal of intangible assets

Qlucore
Press release25.11.2025, 11.00

Invitation to presentation including Q&A session of Qlucore’s interim report for the period 1 May – 31 October 2025

Qlucore
Regulatory press release28.10.2025, 09.30

Qlucore terminates liquidity guarantee agreement

Qlucore
Regulatory press release23.10.2025, 12.30

Bulletin from the annual general meeting of Qlucore AB (publ)

Qlucore
Regulatory press release24.09.2025, 18.30

Interim report 1 May - 31 July 2025

Qlucore
Press release24.09.2025, 10.00

Invitation to presentation including Q&A session of Qlucore’s interim report for the period 1 May – 31 July 2025

Qlucore
Regulatory press release23.09.2025, 17.30

NOTICE OF ANNUAL GENERAL MEETING OF QLUCORE AB (publ)

Qlucore
Regulatory press release08.09.2025, 21.00

Last day of trading in BTA in Qlucore – conversion of BTA into shares

Qlucore
Regulatory press release04.09.2025, 20.00

Qlucore carries out a directed share issue to guarantors

Qlucore
Regulatory press release01.09.2025, 19.00

Qlucore announces outcome of rights issue

Qlucore
Regulatory press release22.08.2025, 09.00

Qlucore secures guarantee commitments as well as additional subscription commitments ahead of rights issue

Qlucore